Curevo Vaccine has closed a $110 million Series B funding round, led by Medicxi, to further develop its shingles vaccine, amezosvatein. The investment will support the expansion of their Phase 2 program to include more participants over age 70.
Gc BiopharmaOrbimedHBM Healthcare InvestmentsSanofi VenturesRA Capital ManagementJanus Henderson InvestorsAdjuvant CapitalMedicxi
Description
Curevo Vaccine has announced the closing of a $110 million Series B funding round aimed at advancing their shingles vaccine, amezosvatein. The round was led by new investor Medicxi and included participation from several other investment firms. This funding will allow Curevo to extend their Phase 2 program into a larger participant count to finalize dose selection for their upcoming Phase 3 program. Additionally, Moncef Slaoui will join Curevo as Board Chair to further guide the company's strategic initiatives.
Who to call at Curevo, and when
A new round usually means Curevo is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Curevo raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Curevo, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Curevo
Location
Bothell, Washington, United States
About
Curevo is a clinical-stage biotechnology company dedicated to developing vaccines with improved tolerability and accessibility. Its lead product is amezosvatein, a non-mRNA adjuvanted sub-unit vaccine to prevent shingles, a serious medical condition involving a painful, blistering skin rash where 10-18% of people also develop serious, long-lasting nerve pain.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Curevo raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BothellBiotechnologyHealthcareMobileSportsPlatforms